Document is current
Any future updates will be listed below
-
Authors
Mons, Elma https://orcid.org/0000-0003-1105-6424
Henderickx, Jannie G. E. https://orcid.org/0000-0001-6533-0324
Sanders, Ingrid M. J. G.
Rader, Anusca G. https://orcid.org/0000-0002-4889-3691
Perkins, Caroline E.
Stel, Florence M. https://orcid.org/0000-0002-3781-8223
van Groesen, Emma https://orcid.org/0000-0003-2991-8256
Smits, Wiep Klaas https://orcid.org/0000-0002-7409-2847
Theriot, Casey M. https://orcid.org/0000-0002-1895-8941
Martin, Nathaniel I. https://orcid.org/0000-0001-8246-3006
-
Funding
Funding for this research was provided by:
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NACTAR 18504)
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NACTAR 20813)
- License Information
-
More Information
Article History
Received: 10 April 2025
Accepted: 5 September 2025
First Online: 10 October 2025
Competing interests
: E.G. and N.I.M. are inventors on a patent application filing WO2021060980A1; title: “Antibiotic compounds”; priority date: 24 September 2019, which includes compounds described in this article. W.K.S. has performed research for Cubist Pharmaceuticals and Acurx Pharmaceuticals and received speaker fees from Promega. C.M.T. has consulted for Vedanta Biosciences, Inc., Summit Therapeutics, and Ferring Pharmaceuticals, Inc. and is on the Scientific Advisory Board for Ancilia Biosciences. All other authors declare that they have no competing interests.
